$3.78
4.85% today
Nasdaq, Apr 02, 09:44 pm CET
ISIN
US25056L1035
Symbol
DSGN

Design Therapeutics Inc Stock price

$3.61
-0.92 20.24% 1M
-1.55 30.00% 6M
-2.57 41.57% YTD
-0.42 10.32% 1Y
-13.53 78.96% 3Y
-16.40 81.98% 5Y
-16.40 81.98% 10Y
Nasdaq, Closing price Tue, Apr 01 2025
-0.26 6.61%
ISIN
US25056L1035
Symbol
DSGN
Sector
Industry

Key metrics

Market capitalization $204.63m
Enterprise Value $-38.52m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.89
P/B ratio (TTM) P/B ratio 0.85
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-62.38m
Free Cash Flow (TTM) Free Cash Flow $-43.45m
Cash position $245.48m
EPS (TTM) EPS $-0.88
Short interest 12.71%
Show more

Is Design Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,807 stocks worldwide.

Design Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a Design Therapeutics Inc forecast:

1x Buy
33%
2x Hold
67%

Analyst Opinions

3 Analysts have issued a Design Therapeutics Inc forecast:

Buy
33%
Hold
67%

Financial data from Design Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs 0.60 0.60
7% 7%
-
-0.60 -0.60
7% 7%
-
- Selling and Administrative Expenses 17 17
15% 15%
-
- Research and Development Expense 44 44
23% 23%
-
-62 -62
20% 20%
-
- Depreciation and Amortization 0.60 0.60
7% 7%
-
EBIT (Operating Income) EBIT -62 -62
20% 20%
-
Net Profit -50 -50
26% 26%
-

In millions USD.

Don't miss a Thing! We will send you all news about Design Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Design Therapeutics Inc Stock News

Neutral
GlobeNewsWire
23 days ago
Initiated Phase 1 Single Ascending Dose Trial of DT-216P2 in Healthy Volunteers; Friedreich Ataxia (FA) Patient Dosing to Begin in mid-2025
Neutral
GlobeNewsWire
about one month ago
CARLSBAD, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in a fireside chat during Leerink's Global Healthcare Conference on Monday, March 10, 2025, at 1:40 p.m. ET in Miami.
Neutral
GlobeNewsWire
5 months ago
CARLSBAD, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in the following upcoming investor conferences:
More Design Therapeutics Inc News

Company Profile

Design Therapeutics, Inc. operates as a biotechnology company that develops therapies for serious degenerative disorders. It is created to design, develop and commercialize a novel class of small molecule therapeutic candidates (GeneTACs) designed to directly address the underlying basis of genetic disease. The company was founded on December 18, 2017 by Pratik Shah and Aseem Z. Ansari and is headquartered in Carlsbad, CA.

Head office United States
CEO Pratik Shah
Employees 54
Founded 2017
Website www.designtx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today